Healthcare IT Today
JANUARY 8, 2024
As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. Drug developers can use these tools to inform routine information-discovery tasks that would require much more time for humans to execute, including benefits-risk evaluation and safety assessments. Dave Latshaw, CEO at BioPhy 1.
Society for Participatory Medicine
FEBRUARY 1, 2023
The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Society for Participatory Medicine
JANUARY 27, 2022
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. The same definition of patient engagement applies to industry, except that the interventions lead to more human centered design and value-based care.
Healthcare IT Today
JANUARY 23, 2024
Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,
Healthcare IT Today
APRIL 25, 2024
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drug development processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.
Healthcare IT Today
MARCH 23, 2023
With the additional funding, Protai will expand its activities to include an oncology drug discovery pipeline, initially focusing on targets with a clearly-defined novel patient population biomarker, derived from its AI proteomics platform. In addition, Protai is supported by leading oncology experts, including Prof.
Healthcare IT Today
NOVEMBER 7, 2023
This ML-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials. bringing new needed treatments to patients.”
Expert insights. Personalized for you.
87 
Let's personalize your content